| 4 | Tropifexor,a selective non-acid farnesoid X receptor agonist,improved nonalcoholic steatohepatitis in a phase 2 trial,but several issues remain to be resolved显示文摘As obesity continues to escalate worldwide,nonalcoholic fatty liver disease(NAFLD)has emerged as the most prevalent form of liver disease,with a reported global prevalence of 30.1%(1).The prevalence of NAFLD,which was around 25%in the 1990s,has been increasing year by year in recent years and has exceeded 35%in the past few years(1).The spectrum of disease includes nonalcoholic fatty liver(NAFL),characterized by macrovesicular hepatic steatosis that may be accompanied by mild inflammation,and nonalcoholic steatohepatitis(NASH),which is additionally characterized by the presence of inflammation and cellular injury(2). | Masato Yoneda Takashi Kobayashi Naohiro Wada Tomohiro Otani Asako Nogami Michihiro Iwaki Atsushi Nakajima | 2023 | Hepatobiliary Surgery and Nutrition2023，12，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员